QHP Capital (“QHP”) today announced an investment in Vector Clinical Trials (“Vector” or the “Company”), a leading clinical research site network led by Founder Dr. Bobby Mocherla. The partnership is ...
Patients in a Phase I/II clinical trial conducted by UMass Chan Medical School of a dual vector gene therapy for GM2 gangliosidosis, which includes Tay-Sachs and Sandhoff diseases, exhibited a ...
Dutch start-up VectorY Therapeutics has been given the green light by the FDA for a phase 1/2 trial of a drug against a target implicated in up to 97% of amyotrophic lateral sclerosis (ALS) cases. VTx ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback